Ro vs Eden: Multi-Vertical Telehealth vs Vertically-Integrated Specialist
Ro and Eden are different shapes of GLP-1 platform serving overlapping audiences. Ro is the multi-vertical incumbent, branded GLP-1 with an insurance concierge plus compounded options across men's health, hair loss, and fertility. Eden is the vertically-integrated specialist that owns its compounding pharmacy and undercuts on cash-pay oral semaglutide. The right pick comes down to whether you have insurance covering Wegovy and how much weight you put on per-fill sourcing transparency.
Ro
3.6Established multi-vertical telehealth with insurance concierge for branded GLP-1
Eden
3.6Vertically-integrated GLP-1 telehealth with notable customer-service caveats
Reviewed by Designing Longevity Editorial·Last verified May 1, 2026
Bottom line
If you have commercial insurance covering Wegovy or Zepbound, Ro is the clearer pick: the insurance concierge can drop your effective monthly cost to $0-$25, which Eden can't match for cash-pay branded. If you're cash-pay and want compounded GLP-1 from a vertically-integrated source, Eden wins on transparency (one company owns the prescription path and the pharmacy fill) and typically on oral semaglutide pricing. The honest counterweight on Eden is the active class-action investigation about possible undisclosed health-data sharing with ad-platform pixels; for privacy-sensitive readers, that's the deciding factor against Eden in favor of TrimRx.
Side-by-side at a glance
Who wins for each use case
We pick a winner per criterion and explain the reasoning. Skip to whichever rows match how you'd actually use the platform.
Insurance pathway for branded Wegovy or Zepbound
Winner: RoRo has a mature insurance concierge that handles prior authorization for branded Wegovy and Zepbound, and with a manufacturer savings card the effective monthly cost can drop to $0-$25 for eligible users. Eden does not run a branded-GLP-1 insurance pathway; the platform is built around cash-pay compounded medication. If insurance is your route, Ro wins outright.
Cash-pay pricing on oral semaglutide
Winner: EdenEden's vertically-integrated model lets it undercut on oral semaglutide because the pharmacy is the company. Ro's compounded GLP-1 runs through partner pharmacies on top of the $145/month membership, which makes the all-in monthly higher than Eden for the same medication and form. For cash-pay oral semaglutide specifically, Eden is typically the better number.
Per-fill sourcing transparency
Winner: EdenEden owns the pharmacy that fills its prescriptions, so 'who compounded my dose' is a non-question. Ro uses a network of partner compounding pharmacies and does not surface the specific partner per fill. For users who weight knowing exactly where their medication came from, vertical integration is a meaningfully cleaner answer.
Regulatory and legal track record
Winner: RoNeither has an FDA warning letter on the GLP-1 line. Ro is flagged for the industry-wide April 2025 FDA compounded topical finasteride alert (different product line in their compounded mix). Eden has an active class-action investigation looking into whether the company shared sensitive health data with third-party advertisers (Meta, TikTok) in possible violation of federal/state privacy laws. We weight an open privacy investigation as more directly applicable to a current Eden user than Ro's industry-wide alert on a hair-loss product line, so Ro wins this row.
Customer service and review platform signals
Winner: RoRo has BBB-Accredited B since 2018 plus the largest ConsumerAffairs review sample in our cohort (4.4/5 across ~21,800 reviews) and a Trustpilot 3.7/5 across ~3,200. Eden's BBB profile is Not Rated with a complaint file open since April 2024 that hasn't been closed. The complaint-handling track record favors Ro.
Multi-vertical platform breadth
Winner: RoRo covers weight loss, men's health, hair loss, fertility, and skincare under one membership model with established operations going back to 2017. Eden is GLP-1-focused with a narrower product line. If you want one provider for several needs, Ro is the obviously broader option.
Privacy posture
Winner: RoEden's class-action investigation is specifically about possible undisclosed sharing of sensitive health data with ad-platform pixels (Meta, TikTok). Ro has no comparable open issue at capture date. For privacy-sensitive users, Ro is the cleaner choice today, though TrimRx beats both on this row.
Rubric scores side-by-side
Same six dimensions we use on every provider profile, weighted to a single 0-5 score. Click through to either profile for the verification details behind each row.
Licensure 20% weight
Accreditation 20% weight
Transparency 20% weight
Product quality 15% weight
Pricing 15% weight
Customer service 10% weight
Pricing in plain terms
Ro's branded-GLP-1 pricing depends on insurance: with eligible commercial coverage and a Novo Nordisk savings card, Wegovy can land at $0-$25/month effective; cash-pay branded is much higher and rarely the right path. Eden runs all-inclusive cash-pay bundles for compounded semaglutide and tirzepatide with no insurance pathway, and tends to undercut Ro's compounded pricing especially on oral semaglutide. The simplest decision rule: insurance covers branded → Ro; cash-pay compounded → Eden (or TrimRx if privacy matters more than oral pricing).
Read the full profiles
This comparison summarizes the head-to-head call. The full provider profiles include verification items, regulatory history, public-review aggregation, and the signup walkthrough.